These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
194 related items for PubMed ID: 7087591
1. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)]. García de Yébenes J, Avila C, Bazán E, García E, Gervás J, Maseda C, Mena M, Muradas V, Ramos JA. Med Clin (Barc); 1982 Apr 01; 78(7):259-64. PubMed ID: 7087591 [No Abstract] [Full Text] [Related]
2. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors]. Cinca I, Serbănescu A, Tudorache B. Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982 Apr 01; 27(4):261-70. PubMed ID: 6222452 [No Abstract] [Full Text] [Related]
4. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients. Admani AK, Verma S, Cordingley GJ, Harris RI. Pharmatherapeutica; 1985 Apr 01; 4(2):132-40. PubMed ID: 4059292 [Abstract] [Full Text] [Related]
5. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)]. Yokochi M, Kondo T, Hirayama K, Narabayashi H, Kuruma I. No To Shinkei; 1979 Mar 01; 31(3):295-304. PubMed ID: 444336 [No Abstract] [Full Text] [Related]
6. [The L-dopa test in Parkinson's disease]. Esteguy M, Bonnet AM, Kefalos J, Lhermitte F, Agid Y. Rev Neurol (Paris); 1985 Mar 01; 141(5):413-5. PubMed ID: 4048732 [Abstract] [Full Text] [Related]
11. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients]. Hironishi M, Miwa H, Kondo T. No To Shinkei; 2002 Feb 01; 54(2):127-32. PubMed ID: 11889758 [Abstract] [Full Text] [Related]
12. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)]. Puca FM, Megna GF, Masi G, Specchio LM. Riv Patol Nerv Ment; 1974 Oct 01; 95(5):676-84. PubMed ID: 4470268 [No Abstract] [Full Text] [Related]
15. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor]. Agnoli A, Casacchia M, Reitano M, Ruggieri S, Barba C, Zamponi A. Minerva Med; 1972 Dec 12; 63(89):4853-61. PubMed ID: 4566743 [No Abstract] [Full Text] [Related]
16. [Secondary effects of prolonged levodopa therapy in Parkinson's disease]. Peiró Grasa A, Grau-Veciana JM. Med Clin (Barc); 1985 Jun 15; 85(3):88-91. PubMed ID: 4021630 [No Abstract] [Full Text] [Related]
20. [Effect of a controlled low-protein diet on the pharmacological response to levodopa and on the plasma levels of L-dopa and amino acids in patients with Parkinson's disease]. Sanchís G, Mena MA, Martín del Río R, Morales B, Casarejo MJ, de Yébenes MJ, Tabernero C, Jiménez A, de Yébenes JG. Arch Neurobiol (Madr); 1991 Jun 15; 54(6):296-302. PubMed ID: 1811460 [Abstract] [Full Text] [Related] Page: [Next] [New Search]